These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

263 related articles for article (PubMed ID: 37239970)

  • 1. TREM2 Expression and Amyloid-Beta Phagocytosis in Alzheimer's Disease.
    La Rosa F; Agostini S; Piancone F; Marventano I; Hernis A; Fenoglio C; Galimberti D; Scarpini E; Saresella M; Clerici M
    Int J Mol Sci; 2023 May; 24(10):. PubMed ID: 37239970
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Early increase of CSF sTREM2 in Alzheimer's disease is associated with tau related-neurodegeneration but not with amyloid-β pathology.
    Suárez-Calvet M; Morenas-Rodríguez E; Kleinberger G; Schlepckow K; Araque Caballero MÁ; Franzmeier N; Capell A; Fellerer K; Nuscher B; Eren E; Levin J; Deming Y; Piccio L; Karch CM; Cruchaga C; Shaw LM; Trojanowski JQ; Weiner M; Ewers M; Haass C;
    Mol Neurodegener; 2019 Jan; 14(1):1. PubMed ID: 30630532
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Expression of the phagocytosis-essential protein TREM2 is down-regulated by an aluminum-induced miRNA-34a in a murine microglial cell line.
    Alexandrov PN; Zhao Y; Jones BM; Bhattacharjee S; Lukiw WJ
    J Inorg Biochem; 2013 Nov; 128():267-9. PubMed ID: 23778113
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Increased cerebrospinal fluid soluble TREM2 concentration in Alzheimer's disease.
    Heslegrave A; Heywood W; Paterson R; Magdalinou N; Svensson J; Johansson P; Öhrfelt A; Blennow K; Hardy J; Schott J; Mills K; Zetterberg H
    Mol Neurodegener; 2016 Jan; 11():3. PubMed ID: 26754172
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Erythromyeloid-Derived TREM2: A Major Determinant of Alzheimer's Disease Pathology in Down Syndrome.
    Raha-Chowdhury R; Henderson JW; Raha AA; Stott SRW; Vuono R; Foscarin S; Wilson L; Annus T; Fincham R; Allinson K; Devalia V; Friedland RP; Holland A; Zaman SH
    J Alzheimers Dis; 2018; 61(3):1143-1162. PubMed ID: 29278889
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The
    Deming Y; Filipello F; Cignarella F; Cantoni C; Hsu S; Mikesell R; Li Z; Del-Aguila JL; Dube U; Farias FG; Bradley J; Budde J; Ibanez L; Fernandez MV; Blennow K; Zetterberg H; Heslegrave A; Johansson PM; Svensson J; Nellgård B; Lleo A; Alcolea D; Clarimon J; Rami L; Molinuevo JL; Suárez-Calvet M; Morenas-Rodríguez E; Kleinberger G; Ewers M; Harari O; Haass C; Brett TJ; Benitez BA; Karch CM; Piccio L; Cruchaga C
    Sci Transl Med; 2019 Aug; 11(505):. PubMed ID: 31413141
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Soluble TREM2 inhibits secondary nucleation of Aβ fibrillization and enhances cellular uptake of fibrillar Aβ.
    Belsare KD; Wu H; Mondal D; Bond A; Castillo E; Jin J; Jo H; Roush AE; Pilla KB; Sali A; Condello C; DeGrado WF
    Proc Natl Acad Sci U S A; 2022 Feb; 119(5):. PubMed ID: 35082148
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Discovery and engineering of an anti-TREM2 antibody to promote amyloid plaque clearance by microglia in 5XFAD mice.
    Zhao P; Xu Y; Fan X; Li L; Li X; Arase H; Tong Q; Zhang N; An Z
    MAbs; 2022; 14(1):2107971. PubMed ID: 35921534
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Investigation of pathology, expression and proteomic profiles in human TREM2 variant postmortem brains with and without Alzheimer's disease.
    Toomey CE; Heywood W; Benson BC; Packham G; Mills K; Lashley T
    Brain Pathol; 2020 Jul; 30(4):794-810. PubMed ID: 32267026
    [TBL] [Abstract][Full Text] [Related]  

  • 10. TREM2 in Alzheimer's disease: Structure, function, therapeutic prospects, and activation challenges.
    Zgorzynska E
    Mol Cell Neurosci; 2024 Mar; 128():103917. PubMed ID: 38244651
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Role of APOE and TREM2 in Alzheimer's Disease-Current Understanding and Perspectives.
    Wolfe CM; Fitz NF; Nam KN; Lefterov I; Koldamova R
    Int J Mol Sci; 2018 Dec; 20(1):. PubMed ID: 30587772
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Soluble TREM2 levels associate with conversion from mild cognitive impairment to Alzheimer's disease.
    Zhao A; Jiao Y; Ye G; Kang W; Tan L; Li Y; Deng Y; Liu J;
    J Clin Invest; 2022 Dec; 132(24):. PubMed ID: 36519540
    [TBL] [Abstract][Full Text] [Related]  

  • 13. TREM2 ectodomain and its soluble form in Alzheimer's disease.
    Yang J; Fu Z; Zhang X; Xiong M; Meng L; Zhang Z
    J Neuroinflammation; 2020 Jul; 17(1):204. PubMed ID: 32635934
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Soluble TREM2 Concentrations in the Cerebrospinal Fluid Correlate with the Severity of Neurofibrillary Degeneration, Cognitive Impairment, and Inflammasome Activation in Alzheimer's Disease.
    Španić Popovački E; Babić Leko M; Langer Horvat L; Brgić K; Vogrinc Ž; Boban M; Klepac N; Borovečki F; Šimić G
    Neurol Int; 2023 Jul; 15(3):842-856. PubMed ID: 37489359
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Soluble TREM2 changes during the clinical course of Alzheimer's disease: A meta-analysis.
    Liu D; Cao B; Zhao Y; Huang H; McIntyre RS; Rosenblat JD; Zhou H
    Neurosci Lett; 2018 Nov; 686():10-16. PubMed ID: 30171911
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Trem2 Deletion Reduces Late-Stage Amyloid Plaque Accumulation, Elevates the Aβ42:Aβ40 Ratio, and Exacerbates Axonal Dystrophy and Dendritic Spine Loss in the PS2APP Alzheimer's Mouse Model.
    Meilandt WJ; Ngu H; Gogineni A; Lalehzadeh G; Lee SH; Srinivasan K; Imperio J; Wu T; Weber M; Kruse AJ; Stark KL; Chan P; Kwong M; Modrusan Z; Friedman BA; Elstrott J; Foreman O; Easton A; Sheng M; Hansen DV
    J Neurosci; 2020 Feb; 40(9):1956-1974. PubMed ID: 31980586
    [No Abstract]   [Full Text] [Related]  

  • 17. Soluble TREM2 ameliorates pathological phenotypes by modulating microglial functions in an Alzheimer's disease model.
    Zhong L; Xu Y; Zhuo R; Wang T; Wang K; Huang R; Wang D; Gao Y; Zhu Y; Sheng X; Chen K; Wang N; Zhu L; Can D; Marten Y; Shinohara M; Liu CC; Du D; Sun H; Wen L; Xu H; Bu G; Chen XF
    Nat Commun; 2019 Mar; 10(1):1365. PubMed ID: 30911003
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CSF sTREM2 in delirium-relation to Alzheimer's disease CSF biomarkers Aβ42, t-tau and p-tau.
    Henjum K; Quist-Paulsen E; Zetterberg H; Blennow K; Nilsson LNG; Watne LO
    J Neuroinflammation; 2018 Nov; 15(1):304. PubMed ID: 30390679
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Up-regulation of TREM2 accelerates the reduction of amyloid deposits and promotes neuronal regeneration in the hippocampus of amyloid beta1-42 injected mice.
    Fan Y; Ma Y; Huang W; Cheng X; Gao N; Li G; Tian S
    J Chem Neuroanat; 2019 Apr; 97():71-79. PubMed ID: 30790627
    [TBL] [Abstract][Full Text] [Related]  

  • 20. TREM2 splice isoforms generate soluble TREM2 species that disrupt long-term potentiation.
    Moutinho M; Coronel I; Tsai AP; Di Prisco GV; Pennington T; Atwood BK; Puntambekar SS; Smith DC; Martinez P; Han S; Lee Y; Lasagna-Reeves CA; Lamb BT; Bissel SJ; Nho K; Landreth GE
    Genome Med; 2023 Feb; 15(1):11. PubMed ID: 36805764
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.